ORYZF News and Press, Oryzon Genomics S.A. From 12/13/21

Robust efficacy - ORR 78%, of which 62% are CR/CRi 77% of CR/CRi lasting more than 6 months Longest remission beyond 1,000 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Enrollment in ALICE completed Dosi...

CBO joins from AIG Asset Management To lead global business strategy and US corporate initiatives from US base MADRID, Spain and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmac...

Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Phase IIb adaptive trial planning to enroll 100 patients Second Phase IIb study of vafidemstat in CNS disorders MADRID, Spain and CAMBRIDGE, Mass...

Iadademstat consistently stronger in viability reduction in AML & SCLC cells Superior target engagement at low concentration in AML & SCLC cells Superior disruption of the Snag-domain protein-protein interactions MADRID, Spain and CAMBRIDGE, Mass....

Jefferies London Healthcare Conference 2021 Evercore ISI 4th Annual HealthCONx Conference 2021 63 th American Society of Hematology 2021 Congress (ASH-2021) MADRID, Spain and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...

MADRID, Spain and CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for...

PORTICO already recruiting in several European countries MADRID, Spain and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases...

Long-term vafidemstat treatment was safe and well tolerated with drug exposures up to 2 years Anti-inflammatory activity observed in vafidemstat-treated patients SATEEN was a pilot, small scale, trial not powered to get definitive efficacy data MADRID, Spain and ...

International Conference on Autism ICA-2021 BIO-Spain 2021 34th European College Neuropsychopharmacology (ECNP) congress 2021 21st Sachs Annual Biotech in Europe Forum 2021 37th Congress of the European Committe for Treatment and Research in Multiple Scle...

HOPE will be the first clinical trial in precision medicine with vafidemstat in neurodevelopmental diseases Multicentric study to assess the efficacy of vafidemstat in Kabuki syndrome patients Expected to start in early 2022 In collaboration with the ...